• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    69 Biggest Movers From Yesterday

    6/6/22 5:31:12 AM ET
    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Turning Point Therapeutics, Inc. (NASDAQ:TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
    • Energy Focus, Inc. (NASDAQ:EFOI) shares gained 48.7% to settle at $1.65 after declining around 9% on Thursday.
    • Galecto, Inc. (NASDAQ:GLTO) jumped 35.2% to settle at $1.96.
    • Yumanity Therapeutics, Inc. (NASDAQ:YMTX) gained 34% to close at $1.42. Yumanity Therapeutics, last month, posted a Q1 loss of $1.24 per share.
    • Houston American Energy Corp. (NYSE:HUSA) climbed 27.5% to close at $5.65.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) climbed 26.4% to close at $12.35 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035.
    • Forian Inc. (NASDAQ:FORA) gained 24.2% to close at $4.05. Forian, last month, posted a Q1 loss of $0.37 per share.
    • Integrated Media Technology Limited (NASDAQ:IMTE) jumped 22.9% to settle at $12.19.
    • Eros STX Global Corporation (NYSE:ESGC) gained 22.2% to settle at $3.03.
    • Harpoon Therapeutics, Inc. (NASDAQ:HARP) climbed 21.2% to close at $2.40.
    • AudioEye, Inc. (NASDAQ:AEYE) jumped 20.8% to close at $4.07. AudioEye's board approved a share buyback of up to $3 million, expiring on June 30, 2024.
    • Global Cord Blood Corporation (NYSE:CO) gained 20.6% to close at $3.46.
    • GreenBox POS (NASDAQ:GBOX) rose 20.3% to settle at $2.55.
    • Predictive Oncology Inc. (NASDAQ:POAI) jumped 21.1% to close at $0.46.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) gained 20.1% to close at $0.7210. Accelerate Diagnostics, last month, posted a Q1 loss of $0.25 per share.
    • Cortexyme, Inc. (NASDAQ:CRTX) gained 20.1% to settle at $3.17.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) jumped 20% to close at $1.11.
    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) gained 19.8% to settle at $0.3725.
    • The Marygold Companies, Inc. (NYSE:MGLD) rose 19.7% to close at $1.76. Marygold Companies, last month, posted Q1 earnings of $0.02 per share.
    • Sprague Resources LP (NYSE:SRLP) shares climbed 19.6% to close at $18.93 after the company announced an agreement to be acquired by Hartree Partners for $19 per common unit.
    • Spark Networks SE (NASDAQ:LOV) gained 19.5% to close at $3.37.
    • IsoPlexis Corporation (NASDAQ:ISO) jumped 19.1% to settle at $2.56.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) climbed 18.9% to settle at $7.85. Iovance Biotherapeutics Director Wayne P Rothbaum acquired a total of 1,000,000 shares at at an average price of $6.60.
    • Wave Life Sciences Ltd. (NASDAQ:WVE) gained 18.8% to close at $1.58.
    • Puma Biotechnology, Inc. (NASDAQ:PBYI) gained 18.2% to close at $2.34. Puma Biotechnology presented final results from the biliary tract cohort of the Phase 2 SUMMIT basket trial of neratinib at ASCO.
    • CuriosityStream Inc. (NASDAQ:CURI) jumped 17.8% to close at $1.79.
    • Atento S.A. (NYSE:ATTO) gained 17.7% to close at $13.03. Atento announced cooperation agreement with investors.
    • Homology Medicines, Inc. (NASDAQ:FIXX) rose 17.3% to settle at $1.76. Homology Medicines recently received FDA orphan drug approval for recombinant adeno-associated viral vector serotype HSC15 for treatment of phenylalanine hydroxylase deficiency.
    • Precision BioSciences, Inc. (NASDAQ:DTIL) gained 17% to close at $1.79.
    • Adaptimmune Therapeutics plc (NASDAQ:ADAP) jumped 16.8% to close at $1.67.
    • Nine Energy Service, Inc. (NYSE:NINE) gained 16.7% to close at $3.92.
    • Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) rose 16.4% to close at $2.27.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) climbed 16.3% to close at $10.57. Nurix Therapeutics will present trial in progress posters for three clinical programs Jun. 4 and 5.
    • Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) gained 16.3% to settle at $3.36.
    • Jowell Global Ltd. (NASDAQ:JWEL) gained 16.1% to close at $3.25. Jowell Global recently posted Q1 sales of $45.10 million.
    • Evofem Biosciences, Inc. (NASDAQ:EVFM) climbed 15.8% to settle at $0.3980.
    • RCM Technologies, Inc. (NASDAQ:RCMT) gained 15.7% to close at $28.00.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) rose 14.8% to close at $4.34.
    • Calavo Growers, Inc. (NASDAQ:CVGW) gained 14% to close at $37.84 following better-than-expected Q2 results.
    • StoneCo Ltd. (NASDAQ:STNE) rose 13.2% to close at $11.80 after the company reported first-quarter revenue growth of 138.6% year-over-year to R$2.07 billion, above the mid-range of the company’s guidance of R$1.85 billion and R$1.9 billion.
    • Boqii Holding Limited (NYSE:BQ) gained 11% to close at $2.1704.
    • Society Pass Incorporated (NASDAQ:SOPA) gained 11% to close at $2.32 after the company announced it acquired Gorilla Networks.
    • Quanex Building Products Corporation (NYSE:NX) climbed 10.5% to close at $22.91 after the company reported better-than-expected Q2 results and issued FY22 sales guidance above estimates.
    • Mirati Therapeutics, Inc. (NASDAQ:MRTX) rose 10.1% to close at $44.33.
    • Kubient, Inc. (NASDAQ:KBNT) rose 8.5% to close at $1.08.
    • Okta, Inc. (NASDAQ:OKTA) rose 5% to close at $98.38 after the company reported better-than-expected Q1 sales results. The company also issued Q2 sales guidance above analyst estimates.

     

     

    Losers

    • Bit Origin Limited (NASDAQ:BTOG) shares dropped 44.4% to close at $0.4780 on Friday as the company reported a proposed underwritten public offering of ordinary shares.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares dipped 36.1% to close at $0.3850 after the company reported pricing of $4 million underwritten public offering.
    • Rallybio Corporation (NASDAQ:RLYB) dropped 30% to close at $9.26. Rallybio announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) dropped 22% to close at $0.78. Zosano Pharma recently announced it filed a voluntary petition for relief under chapter 11.
    • NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) fell 20.4% to settle at $1.09.
    • Novavax, Inc. (NASDAQ:NVAX) fell 20% to close at $44.76. The U.S. FDA published briefing documents on Novavax Covid-19 vaccine for individuals aged 18 and older.
    • JOANN Inc. (NASDAQ:JOAN) dropped 19.5% to close at $6.36 after the company said Q1 EPS results were lower year over year and reported worse-than-expected Q1 sales results.
    • Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) fell 19.2% to close at $1.18.
    • HashiCorp, Inc. (NASDAQ:HCP) shares fell 17.6% to close at $34.00 after the company reported Q1 earnings results and issued guidance.
    • Grom Social Enterprises, Inc. (NASDAQ:GROM) dipped 15.7% to close at $0.5901.
    • Bright Green Corporation (NASDAQ:BGXX) dropped 15.6% to close at $3.04.
    • Invitae Corporation (NYSE:NVTA) dipped 15.2% to settle at $3.02. Piper Sandler initiated coverage on Invitae with an Underweight rating and announced a price target of $2.5.
    • Fast Radius, Inc. (NASDAQ:FSRD) fell 15.1% to settle at $0.45.
    • Mercurity Fintech Holding Inc. (NASDAQ:MFH) dipped 14.6% to close at $1.05.
    • Dave Inc. (NASDAQ:DAVE) dropped 13.5% to close at $1.99.
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) fell 12.9% to close at $0.7345.
    • Gravitas Education Holdings, Inc. (NYSE:GEHI) fell 11% to close at $0.62.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 10% to close at $0.30.
    • Context Therapeutics Inc. (NASDAQ:CNTX) fell 8.7% to close at $2.00.
    • Wayfair Inc. (NYSE:W) dipped 8.6% to close at $58.30.
    • Zumiez Inc. (NASDAQ:ZUMZ) fell 8.8% to settle at $31.16 after the company reported worse-than-expected Q1 EPS results and issued Q2 EPS and sales guidance below analyst estimates.
    • Impac Mortgage Holdings, Inc. (NYSE:IMH) fell 6.7% to close at $0.7702.
    • Talkspace, Inc. (NASDAQ:TALK) fell 6.3% to close at $1.65 after jumping 34% on Thursday.
    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ADAP
    $AEYE
    $AMLX

    CompanyDatePrice TargetRatingAnalyst
    Okta Inc.
    $OKTA
    4/20/2026$90.00Equal Weight → Overweight
    Barclays
    Okta Inc.
    $OKTA
    4/16/2026$85.00Mkt Perform → Outperform
    Raymond James
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    Olema Pharmaceuticals Inc.
    $OLMA
    3/27/2026Peer Perform
    Wolfe Research
    Olema Pharmaceuticals Inc.
    $OLMA
    3/19/2026Buy
    Jefferies
    Okta Inc.
    $OKTA
    3/19/2026$100.00Outperform
    Macquarie
    Okta Inc.
    $OKTA
    3/6/2026$97.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Georgevich Kelly bought $99,398 worth of shares (16,850 units at $5.90), increasing direct ownership by 13% to 144,981 units (SEC Form 4)

    4 - AUDIOEYE INC (0001362190) (Issuer)

    3/17/26 4:35:45 PM ET
    $AEYE
    Computer Software: Prepackaged Software
    Technology

    Director Hawkins James B bought $219,744 worth of shares (38,000 units at $5.78), increasing direct ownership by 22% to 207,517 units (SEC Form 4)

    4 - AUDIOEYE INC (0001362190) (Issuer)

    3/12/26 4:20:55 PM ET
    $AEYE
    Computer Software: Prepackaged Software
    Technology

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Okta upgraded by Barclays with a new price target

    Barclays upgraded Okta from Equal Weight to Overweight and set a new price target of $90.00

    4/20/26 8:21:07 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Okta upgraded by Raymond James with a new price target

    Raymond James upgraded Okta from Mkt Perform to Outperform and set a new price target of $85.00

    4/16/26 7:58:53 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target

    Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

    4/9/26 8:40:45 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Conine Steven

    4 - Wayfair Inc. (0001616707) (Issuer)

    4/21/26 5:05:10 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by Shah Niraj

    4 - Wayfair Inc. (0001616707) (Issuer)

    4/21/26 5:03:14 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by Miller Kevin D

    4 - RCM TECHNOLOGIES, INC. (0000700841) (Issuer)

    4/21/26 4:19:16 PM ET
    $RCMT
    Professional Services
    Consumer Discretionary

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    SEC Filings

    View All

    SEC Form 6-K filed by StoneCo Ltd.

    6-K - StoneCo Ltd. (0001745431) (Filer)

    4/23/26 5:17:45 PM ET
    $STNE
    EDP Services
    Technology

    SEC Form 20-F filed by StoneCo Ltd.

    20-F - StoneCo Ltd. (0001745431) (Filer)

    4/23/26 5:04:45 PM ET
    $STNE
    EDP Services
    Technology

    SEC Form 144 filed by Wayfair Inc.

    144 - Wayfair Inc. (0001616707) (Subject)

    4/23/26 4:15:19 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on April 20, 2026, the Compensation Committee of Precision's Board of Directors approved the grant of an inducement award of 7,094 restricted stock units ("RSUs") to a new employee under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan") in connection with their commencement of employment. The award was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee to commence service with Precision.

    4/24/26 7:01:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    StoneCo Files Its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

    George Town, Grand Cayman--(Newsfile Corp. - April 23, 2026) - StoneCo Ltd. (NASDAQ:STNE) ("Stone" or "the Company") hereby informs its shareholders and the market that has filed today, April 23, its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC").The report is available on the SEC's website, at www.sec.gov, and on StoneCo's Investor Relations website, at https://investors.stone.co. About StoneCoStone Co. is a leading provider of financial technology solutions that empower merchants to conduct commerce seamlessly across multiple channels and help them grow their businesses with our payments, banking, and cre

    4/23/26 6:02:00 PM ET
    $STNE
    EDP Services
    Technology

    Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour afte

    4/23/26 4:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer

    Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in this fieldMr. Tyson is appointed as NRx anticipates approval of an ANDA for preservative-free ketamine and near term submission of a New Drug Application to expand ketamine labeling to encompass depression and suicidality. WILMINGTON, Del., April 13, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the appointment of Glenn Tyson as the company's first

    4/13/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of GrowthRALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

    4/8/26 8:00:00 AM ET
    $CNTX
    $NEOG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Financials

    Live finance-specific insights

    View All

    Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour afte

    4/23/26 4:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AudioEye Announces Preliminary First Quarter 2026 Results and Sets First Quarter 2026 Earnings Call

    Forty-First Consecutive Period of Record RevenueTUCSON, Ariz., April 23, 2026 /PRNewswire/ -- AudioEye, Inc. (NASDAQ:AEYE) ("AudioEye" or the "Company"), an industry-leading digital accessibility company, provided its preliminary outlook for revenue, annual recurring revenue (ARR), and adjusted EBITDA for the first quarter of 2026. "AudioEye is off to a strong start in 2026. We had another strong quarter of ARR growth, delivering 12% annualized sequential growth and reaching an estimated $41.2 million of ARR. We also exceeded adjusted EBITDA guidance in the first quarter and exp

    4/23/26 8:00:00 AM ET
    $AEYE
    Computer Software: Prepackaged Software
    Technology

    Dave to Host First Quarter 2026 Conference Call on May 5, 2026 at 5:00 p.m. ET

    Los Angeles, April 23, 2026 (GLOBE NEWSWIRE) -- Dave Inc. (NASDAQ:DAVE) ("Dave" or the "Company"), one of the nation's leading neobanks, will host a conference call on Tuesday, May 5, 2026, at 5:00 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2026. The Company's results will be reported in a press release on the same day, prior to the conference call. Dave management will host the conference call, followed by a question-and-answer period. The conference call details are as follows: Date: Tuesday, May 5, 2026Time: 5:00 p.m. Eastern timeConference Call Registration: linkWebcast: link The conference call will also be available for replay in the E

    4/23/26 8:00:00 AM ET
    $DAVE
    Finance: Consumer Services
    Finance

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials